Citations 14
Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.
Leroy, Karen , Jaïs, Jean‐Philippe , Ruminy, Philippe , Réyès, Cécile , Wright, George, Gascoyne, Randy D. , Staudt, Louis M. , Tilly, Hervé , Salles, Gilles , Molina, Thierry Jo , LYSA, Wright, George W. , Salles, Gilles A , Gentien, David , Scott, David W. , Rimsza, Lisa M. , Haïoun, Corinne , Gaulard, Philippe , Jardin, Fabrice , LYSA, Wright, George
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7547-7547
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Clot, Guillem , Jares, Pedro , Giné, Eva , Navarro, Alba , Pinyol, Magda, Martin‐García, David , Demajo, Santiago , Espinet, Blanca , Salar, Antonio , Ferrer, Ana , Muntañola, Ana , Aymerich, Marta , Rauert‐Wunderlich, Hilka , Gascoyne, Randy D. , Delabie, Jan , López‐Guillermo, Armando , Ott, German , Wright, George W. , Staudt, Louis M. , Rosenwald, Andreas , Beà, Sı́lvia , Martín-Garcia, David , Demajo, Santiago , Salar, Antonio , Ferrer, Ana , Jaffe, Elaine S , Connors, Joseph M , Delabie, Jan , López-Guillermo, Armando , Beà, Sílvia , Campo, Elías , Royo, Cristina , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Rimsza, Lisa M. , Campo, Elı́as , Espinet, Blanca , Wright, George
Blood | May 16, 2018 | Volume: 132 | Issue: 4 | Pages: 413-422
Key PointsA new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.
MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN‐FIXED, PARAFFIN‐EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT
Rosenwald, Andreas , Ott, German , Ramsower, Colleen , Braziel, Rita M., Weisenburger, Dennis D. , Chan, John, Cook, James R. , Fu, Kai , Greiner, Timothy C. , Smeland, Erlend B., Glinsmann‐Gibson, Betty, Gascoyne, Randy D. , Staudt, Louis M. , Mottok, Anja , Wright, George W. , Campo, Elı́as , Delabie, Jan , Song, Joo Y. , Chan, J.W., Holte, Harald , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Steidl, Christian , Rimsza, Lisa M.
Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 59-60
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Czuczman, Myron S., Trněný, Marek , Davies, Andrew , Rule, Simon , Linton, Kim , Wagner‐Johnston, Nina D. , Gascoyne, Randy D. , Slack, Graham W. , Eberhard, David A., Hernandez‐Ilizaliturri, Francisco J. , Salles, Gilles , Zinzani, Pier Luigi , Wright, George W. , Staudt, Louis M. , Yang, Yandan , Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan , Hagner, Patrick R. , Fustier, Pierre , Song, Dale, Lewis, Ian D., Brousset, Pierre , Witzig, Thomas E. , Williams, P. Mickey , Lih, Chih‐Jian, Zinzani, Pier Luigi , Salles, Gilles A , Davies, Andrew , Trnĕný, Marek , Linton, Kim M , Wright, George
Clinical Cancer Research | April 5, 2017 | Volume: 23 | Issue: 15 | Pages: 4127-4137
Abstract Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin). Crossover to lenalidomide was permitted for IC-treated patients with radiologically confirmed progressive disease. The primary endpoint was overall response rate (ORR). Progression-free survival (PFS), overall survival, and subtype analysis [GCB vs. activated B-cell (ABC)] using gene expression profiling (GEP) were exploratory endpoints. Results: Stage 1: 102 DLBCL patients (by IHC: non-GCB, n = 54; GCB, n = 48) received ≥1 dose of lenalidomide or IC. Hematologic treatment-emergent adverse events with lenalidomide versus IC included neutropenia (42.6%; 36.4%), anemia (33.3%; 47.3%), thrombocytopenia (24.1%; 43.6%), and leukopenia (5.6%; 12.7%), respectively. Overall, lenalidomide-treated patients had an ORR of 27.5% versus 11.8% in IC (ORRs were similar regardless of IHC-defined DLBCL subtype). Median PFS was increased in patients receiving lenalidomide (13.6 weeks) versus IC (7.9 weeks; P = 0.041), with greater improvements in non-GCB patients (15.1 vs. 7.1 weeks, respectively; P = 0.021) compared with GCB (10.1 vs. 9.0 weeks, respectively; P = 0.550). Conclusions: The clinical benefit of lenalidomide monotherapy in DLBCL patients was more evident in the non-GCB subtype. Exploratory analyses suggest that this preferential benefit was more pronounced in the GEP-defined ABC population, demonstrating a need for additional studies of lenalidomide in DLBCL using GEP subtyping. Clin Cancer Res; 23(15); 4127–37. ©2017 AACR.